AMAL Therapeutics, a Boehringer Ingelheim company, develops unique therapeutic cancer vaccines. Its peptide/protein-based immunization technology platform KISIMA® is self-adjuvanting and enables the assembly within one chimeric fusion protein of three elements essential to generate potent immunity: a cell-penetrating peptide for antigen delivery, a TLR- peptide agonist as adjuvant and a modular multi-antigenic cargo that can be tailored to various indications.
